代谢功能障碍相关脂肪性肝病中肝细胞癌发病率:重建个体患者数据Meta分析
该研究通过重建已发表Kaplan-Meier曲线的个体参与者数据,纳入26项研究共3,995,728人,采用随机效应模型汇总MASLD患者肝细胞癌累积发病率。结果显示合并晚期纤维化者10年累积发病率在行政数据库研究中为8.8%、医院/诊所研究中为48.5%,而无晚期纤维化者分别为1.3%和18.3%;晚期纤维化者HCC风险显著更高。
要点
- MASLD合并晚期纤维化者10年HCC累积发病率行政数据库8.8%、医院/诊所48.5%。
- 无晚期纤维化者10年HCC累积发病率行政数据库1.3%、医院/诊所18.3%。
- 晚期纤维化者HCC风险显著高于无晚期纤维化者,行政数据库HR 11.09、医院/诊所HR 10.50。
核心结论
- MASLD患者中HCC发病率在合并晚期纤维化者中升高,重建个体患者数据Meta分析提供了更新的发病率估计。
研究设计与样本
- 检索Medline和Embase从建库至2024年11月,筛选4951篇文章,纳入26项研究共3,995,728人。
- 从已发表Kaplan-Meier曲线重建个体参与者数据,采用随机效应模型对时间事件数据汇总HCC累积发病率。
主要发现
- MASLD合并已知晚期纤维化者1、3、5、10年HCC累积发病率在行政数据库研究中分别为0.8%、2.4%、3.9%、8.8%,在医院/诊所研究中分别为3.9%、11.7%、21.0%、48.5%。
- MASLD无晚期纤维化者1、3、5、10年HCC累积发病率在行政数据库研究中分别为0.1%、0.5%、0.7%、1.3%,在医院/诊所研究中分别为1.6%、4.7%、8.2%、18.3%。
- 选择偏倚可能贡献医院/诊所研究中升高的风险。
- 晚期纤维化患者HCC风险显著高于无晚期纤维化者,行政数据库研究HR 11.09(95%CI 2.68-45.89,P < .001),医院/诊所研究HR 10.50(95%CI 3.19-34.51,P < .001)。
临床怎么用
- 上述数据可能对HCC监测的进一步研究和未来监测算法的开发具有启示意义。
局限性
- 选择偏倚可能贡献医院/诊所研究中升高的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the fastest rising etiology of hepatocellular carcinoma (HCC). The time-dependent incidence of HCC in people with MASLD has not been reported. We aimed to provide robust estimates for HCC incidence in MASLD. METHODS: Medline and Embase were searched from inception to November 2024. Individual participant data were reconstructed from published Kaplan-Meier curves, and a pooled analysis of cumulative HCC incidence from time-to-event data was performed using a random-effects model. RESULTS: We screened 4951 articles and included 26 studies (3,995,728 individuals). The 1-, 3-, 5-, and 10-year cumulative incidence of HCC in people with MASLD and known advanced fibrosis was 0.8%, 2.4%, 3.9%, and 8.8%, respectively, in administrative database studies, and 3.9%, 11.7%, 21.0% and 48.5%, respectively, in hospital/clinic-based studies. The 1-, 3-, 5-, and 10-year cumulative incidence of HCC in people with MASLD but without advanced fibrosis was 0.1%, 0.5%, 0.7%, and 1.3%, respectively, in administrative database studies, and 1.6%, 4.7%, 8.2%, and 18.3%, respectively, in hospital/clinic-based studies. Selection bias may contribute to the elevated risk in hospital/clinic-based studies. The risk of HCC in patients with advanced fibrosis was significantly higher compared with those without advanced fibrosis in both administrative database (hazard ratio [HR], 11.09; 95% confidence interval [CI], 2.68-45.89; P < .001) and hospital/clinic-based studies (HR, 10.50; 95% CI, 3.19-34.51; P < .001). CONCLUSIONS: This reconstructed individual participant data meta-analysis provides updated estimates for HCC incidence in people with MASLD. The incidence of HCC is elevated in people with MASLD and advanced fibrosis. These data may have implications for further research in HCC surveillance and future development of surveillance algorithms.
引用
- Lim RY, Tan FXN, Ho GJK, et al. Incidence of Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Reconstructed Individual Patient Data Meta-Analysis. Clin Gastroenterol Hepatol. 2025. PMID: 40935097. doi:10.1016/j.cgh.2025.08.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。